AMGEN INC. DL-,0001/ US0311621009 /
23/05/2024 18:43:37 | Chg. +0.700 | Volume | Bid18:44:06 | Ask18:44:06 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
285.850EUR | +0.25% | 79 Turnover: 22,501.450 |
285.550Bid Size: 210 | 285.850Ask Size: 210 | 153.39 bill.EUR | - | - |
GlobeNewswire
22/05
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...
GlobeNewswire
21/05
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
GlobeNewswire
21/05
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a bios...
GlobeNewswire
15/05
Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
GlobeNewswire
14/05
Accumulus Synergy Sponsors Revolutionary Healthcare Data Standard, Advancing Towards Global Dossier
GlobeNewswire
14/05
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...
GlobeNewswire
13/05
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
09/05
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08/05
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 ...
GlobeNewswire
08/05
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08/05
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination ...